LAUSR

References 1 Napolitano S, Brancaccio G, Argenziano G, et al. It is finally time for adjuvant therapy in melanoma. Cancer Treat Rev 2018; 69: 101–111. 2 Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 1990; 2016: 190–209. 3 Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74: 455–461.e1.. 4 Hwang SJE, Fern andez-Pe~ nas P. Adverse reactions to biologics: melanoma (Ipilimumab, Nivolumab, Pembrolizumab). Curr Probl Dermatol 2018; 53: 82–92. 5 Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714–1768. 6 Kanitakis J. Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. Eur J Dermatol 2014; 24: 533–544. 7 Goulding JMR, Teoh JK, Carr RA, et al. Eruptive disseminated superficial porokeratosis with rapid resolution: a drug-induced phenomenon? Clin Exp Dermatol 2009; 34: 895– 897. 8 Lopes LN, Gouveia AI, Soares-Almeida L, et al. Porokeratosis and malignant melanoma: a causal or incidental association? Indian Dermatol Online J 2015; 6: 451–452. 9 Kanekura T, Yoshii N. Eruptive pruritic papular porokeratosis: a pruritic variant of porokeratosis. J Dermatol 2006; 33: 813– 816. 10 Mangas C, Espeli V, Blum R. A case of eruptive disseminated porokeratosis in a cancer patient after trastuzumab and exemestane treatment: cancer related or drug induced phenomenon? Actas Dermosifiliogr 2018; 109: 559–560.